Effective January 1, 2023, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will update its Intra-Articular Hyaluronan Knee Injection utilization criteria to prefer Orthovisc for the treatment of osteoarthritis of the knee, in addition to the current preferred products, Synvisc and/or Synvisc-One. Durolane and Gelsyn-3 will no longer be preferred products. Any existing Durolane or Gelsyn-3 prior authorizations will be active through the original prior authorization approval date.
Learn more about Intra Hyaluronan Injections (PDF).
Actions Required Due to These Changes
Providers with members on impacted drugs should utilize these preferred products before using non-preferred products. Any members who are currently using non-preferred Durolane or Gelsyn-3 should be moved to our preferred products once their existing authorization ends.
Please continue to submit all requests via the CMM Portal for fastest processing times.
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.